Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Beyond glycemic control: New guidance on cardio-renal protection.

Literature DB >> 30797784

Beyond glycemic control: New guidance on cardio-renal protection.

Athanasios D Anastasilakis¹, Elliot Sternthal², Christos S Mantzoros³.

Abstract

Keywords: Cardiovascular; Diabetes mellitus; GLP-1 receptor agonist; Limb amputation; SGLT-2 inhibitor

Mesh：

Substances：

Year: 2019 PMID： 30797784 DOI： 10.1016/j.metabol.2019.02.004

Source DB: PubMed Journal: Metabolism ISSN： 0026-0495 Impact factor: 8.694

Keyword Cloud
Cited

× No keyword cloud information.

2 in total

1. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE^(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis.

Authors: Narjes Nasiri-Ansari; Chrysa Nikolopoulou; Katerina Papoutsi; Ioannis Kyrou; Christos S Mantzoros; Georgios Kyriakopoulos; Antonios Chatzigeorgiou; Vassiliki Kalotychou; Manpal S Randeva; Kamaljit Chatha; Konstantinos Kontzoglou; Gregory Kaltsas; Athanasios G Papavassiliou; Harpal S Randeva; Eva Kassi
Journal: Int J Mol Sci Date: 2021-01-15 Impact factor: 5.923

2. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.

Authors: Sebastiano Bruno Solerte; Francesca D'Addio; Roberto Trevisan; Elisabetta Lovati; Antonio Rossi; Ida Pastore; Marco Dell'Acqua; Elio Ippolito; Cristiana Scaranna; Rosalia Bellante; Silvia Galliani; Alessandro Roberto Dodesini; Giuseppe Lepore; Francesca Geni; Roberta Maria Fiorina; Emanuele Catena; Angelo Corsico; Riccardo Colombo; Marco Mirani; Carlo De Riva; Salvatore Endrio Oleandri; Reza Abdi; Joseph V Bonventre; Stefano Rusconi; Franco Folli; Antonio Di Sabatino; Gianvincenzo Zuccotti; Massimo Galli; Paolo Fiorina
Journal: Diabetes Care Date: 2020-09-29 Impact factor: 19.112

2 in total

Beyond glycemic control: New guidance on cardio-renal protection.

1. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis.

2. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.

1. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE^(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis.